BerGenBio 過去の業績

過去基準チェック /06

BerGenBioは3.2%の年平均成長率で業績を伸ばしているが、Biotechs業界はgrowingで7.7%毎年増加している。売上は減少しており、年平均65.8%の割合である。

主要情報

3.2%

収益成長率

28.8%

EPS成長率

Biotechs 業界の成長	20.9%
収益成長率	-65.8%
株主資本利益率	-99.3%
ネット・マージン	-29,230.1%
次回の業績アップデート	19 Feb 2025

Recent updates

It's Unlikely That The CEO Of BerGenBio ASA (OB:BGBIO) Will See A Huge Pay Rise This Year

Mar 13

We're Interested To See How BerGenBio (OB:BGBIO) Uses Its Cash Hoard To Grow

Feb 11

What Kind Of Investors Own Most Of BerGenBio ASA (OB:BGBIO)?

Dec 21

収支内訳

BerGenBio の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

OB:BGBIO 収益、費用、利益 ( )NOK Millions
日付	収益	収益	G+A経費
30 Sep 24	1	-152	42
30 Jun 24	1	-155	44
31 Mar 24	1	-155	48
31 Dec 23	0	-190	51
30 Sep 23	0	-226	60
30 Jun 23	0	-258	60
31 Mar 23	0	-293	64
31 Dec 22	0	-302	64
30 Sep 22	1	-294	62
30 Jun 22	1	-304	74
31 Mar 22	1	-309	71
31 Dec 21	1	-309	71
30 Sep 21	1	-314	71
30 Jun 21	1	-311	61
31 Mar 21	1	-290	57
31 Dec 20	1	-257	52
30 Sep 20	0	-241	48
30 Jun 20	0	-218	40
31 Mar 20	0	-204	38
31 Dec 19	9	-199	35
30 Sep 19	11	-193	32
30 Jun 19	11	-186	36
31 Mar 19	11	-182	33
31 Dec 18	2	-192	32
30 Sep 18	0	-188	32
30 Jun 18	0	-186	29
31 Mar 18	0	-171	28
31 Dec 17	0	-182	28
30 Sep 17	0	-162	21
30 Jun 17	0	-142	16
31 Mar 17	0	-175	14
31 Dec 16	0	-130	12
30 Sep 16	0	-127	18
30 Jun 16	0	-128	22
31 Mar 16	0	-82	24
31 Dec 15	0	-72	23
30 Sep 15	0	-70	20
30 Jun 15	0	-64	17
31 Mar 15	1	-57	15
31 Dec 14	1	-58	15

質の高い収益: BGBIOは現在利益が出ていません。

利益率の向上: BGBIOは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: BGBIOは利益を出していないが、過去 5 年間で年間3.2%の割合で損失を削減してきた。

成長の加速: BGBIOの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: BGBIOは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -18.2% ) と比較することは困難です。

株主資本利益率

高いROE: BGBIOは現在利益が出ていないため、自己資本利益率 ( -99.29% ) はマイナスです。

BerGenBio 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

BerGenBio ASA to Report Q4, 2024 Results on Feb 19, 2025

BerGenBio ASA to Report Q1, 2023 Results on Jun 22, 2023

BerGenBio ASA to Report Q3, 2023 Results on Nov 14, 2023

BerGenBio ASA to Report Q4, 2020 Results on Feb 10, 2021

BerGenBio ASA to Report Q3, 2021 Results on Nov 16, 2021

BerGenBio ASA to Report Q2, 2020 Results on Aug 18, 2020

Recent updates

BerGenBio ASA Appoints Olav Hellebø as CEO, Effective November 21, 2024

New major risk - Share price stability

Martin Olin to Step Down from BerGenBio ASA as CEO

BerGenBio ASA Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients

Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

Companies Like BerGenBio (OB:BGBIO) Could Be Quite Risky

BerGenBio ASA Announces Closure of EU-Solidact Bemcentinib Study Arm in Hospitalized COVID-19 Patients

BerGenBio ASA Announces Final Bemcentinib Phase 2 Data in AML and MDS Presented at the 2023 ASH Meeting

BerGenBio ASA has completed a Follow-on Equity Offering in the amount of €240.87 million.

Here's Why BerGenBio (OB:BGBIO) Must Use Its Cash Wisely

New major risk - Financial position

BerGenBio ASA to Report Q4, 2024 Results on Feb 19, 2025

BerGenBio ASA Announces Full Results of its Phase 2 BGBC008 Study of Bemcentinib and Pembrolizumab in Second Line Non-Small Cell Lung Cancer

BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

Price target decreased by 63% to kr5.68

New major risk - Shareholder dilution

BerGenBio ASA has completed a Follow-on Equity Offering in the amount of NOK 250 million.

Chief Executive Officer exercised options to buy kr323k worth of stock.

BerGenBio Announces Data from Bemcentinib Trial in Mesothelioma Presented at ASCO

BerGenBio ASA Announces Resignation of Francois Thomas from the Board of Directors

BerGenBio ASA to Report Q1, 2023 Results on Jun 22, 2023

High number of new and inexperienced directors

BerGenBio ASA Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients

BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely

BerGenBio ASA Announces Board Appointments

BerGenBio ASA to Report Q3, 2023 Results on Nov 14, 2023

Price target decreased to kr12.00

BerGenBio ASA Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations

BerGenBio ASA Announces First Patient Randomized in Bemcentinib Trial in Eu-Solidact Platform for Hospitalized Covid-19 Patients

Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

BerGenBio ASA Provides Update on Clinical Development

Chairman of the Board recently bought kr268k worth of stock

Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?

Consensus forecasts updated

Price target decreased to kr47.50

BerGenBio ASA Announces Complete Data Analysis of Accord2 Phase II Bemcentinib Study in Hospitalized Covid-19 Patients - Primary Efficacy Endpoint Met

Bergenbio Presents Bemcentinib Covid-19 Clinical Trial Data At Eccmid 2022

BerGenBio ASA Appoints Cristina Oliva as Chief Medical Officer, Effective April 25, 2022

Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?

High number of new and inexperienced directors

Chief Executive Officer recently bought kr204k worth of stock

We're Not Very Worried About BerGenBio's (OB:BGBIO) Cash Burn Rate

BerGenBio ASA Completes Recruitment of Phase II AML Study ((BGBC003)

Chief Executive Officer Richard Godfrey has left the company

BerGenBio ASA Presents Encouraging Combined Data for Bemcentinib from Two Phase II Covid-19 Studies At Eccmid

BerGenBio ASA Updates Preliminary Survival Data from the Ongoing Phase II Study of Bemcentinib

BerGenBio ASA Receives Food and Drug Administration Fast Track Designation for Bemcentinib / Anti-Pd-(L)1 Combination in NSCLC

BerGenBio ASAPresents Data from Phase I/II Bemcentinib/Erlotinib Combination Trial in NSCLC

BerGenBio ASA to Present Data from Phase I/II Bemcentinib/Erlotinib Combination Trial in NSCLC at ASCO Meeting

BerGenBio ASA Announces Top Line Data from Phase II Trial Assessing Bemcentinib in Hospitalised Covid-19 Patients

BerGenBio ASA Announces Pre-Clinical COVID-19 Data Presented at Virtual Immunology 2021

It's Unlikely That The CEO Of BerGenBio ASA (OB:BGBIO) Will See A Huge Pay Rise This Year

BerGenBio ASA Completes Enrolment into Latest Cohort of Phase II Bemcentinib Combination Study in Refractory NSCLC

BerGenBio ASA Announces Start of Phase 1B Trial of Anti-AXL Antibody Tilvestamab (BGB149)

BerGenBio ASA Closes Recruitment into Trial Assessing Bemcentinib in Covid-19 Patients

New 90-day low: kr30.75

Analysts update estimates

We're Interested To See How BerGenBio (OB:BGBIO) Uses Its Cash Hoard To Grow

Revenue and earnings in line with expectations

BerGenBio ASA Announces Second Data Monitoring Committee Recommends Continuation of Bergenbio's BGBC020 Trial Assessing Bemcentinib in COVID-19 Patients

Price target raised to kr63.00

BerGenBio ASA Presents an Update from Its Phase II Study of Bemcentinib in Combination with Anti-PD-1 Therapy Pembrolizumab (Bgbc008)

Bergenbio to Present Updates from Ongoing Phase II Bemcentinib Combination Study in Refractory NSCLC At WCLC 2020

New 90-day high: kr37.30

BerGenBio ASA to Report Q4, 2020 Results on Feb 10, 2021

BerGenBio ASA to Report Q3, 2021 Results on Nov 16, 2021

What Kind Of Investors Own Most Of BerGenBio ASA (OB:BGBIO)?

New 90-day high: kr36.00

BerGenBio ASA Presents Updated Clinical Data from Two Phase II Studies of Bemcentinib in AML and MDS Patients at ASH 2020

過去基準チェック /06